{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000064","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.956424+00:00","generated_at":"2026-05-23T08:08:25.931587+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ivonescimab + chemo beats tislelizumab + chemo in Phase III squamous NSCLC trial (HARMONi-6)","bullets":["Primary endpoint PFS met: statistically significant and clinically meaningful improvement by BICR versus tislelizumab combo.","PFS benefit observed in both PD-L1 positive and PD-L1 negative tumors.","No new safety signals identified; full data set to be presented at upcoming medical conference.","Second ivonescimab Phase III to show superiority over PD-(L)1 therapy (after HARMONi-2 in PD-L1+ monotherapy).","Summit enrolling HARMONi-3 global Phase III vs pembrolizumab combo in 1L metastatic NSCLC with registrational intent."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000064","json":"https://secwatch.observer/filing/0001599298-25-000064.json","markdown":"https://secwatch.observer/filing/0001599298-25-000064.md","text":"https://secwatch.observer/filing/0001599298-25-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000064/0001599298-25-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000064/smmt-20250423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:08:25.931587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}